Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 7, 2015, Pages 672-687

  Yang, Yue ^a   Keene, C Dirk ^a   Peskind, Elaine R ^b,c   Galasko, Douglas R ^d   Hu, Shu Ching ^a   Cudaback, Eiron ^a   Wilson, Angela M ^a   Li, Ge ^b   Yu, Chang En ^a,c   Montine, Kathleen S ^a   Zhang, Jing ^a   Baird, Geoffrey S ^a   Hyman, Bradley T ^e   Montine, Thomas J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer disease; Biomarkers; Cerebrospinal fluid; Cognitive impairment; Neurodegenerative disease; Parkinson disease

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CLUSTERIN; LIPID; LIPOCORTIN 5; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; TAU PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETRY; GENOTYPE; GLIAL CELL CULTURE; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MOUSE; NERVE CELL CULTURE; NONHUMAN; PARKINSON DISEASE; PARTICLE SIZE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGE; ANIMAL; C57BL MOUSE; EXOSOME; GENETICS; KNOCKOUT MOUSE; METABOLISM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; EXOSOMES; FEMALE; FLOW CYTOMETRY; HUMANS; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; PEPTIDE FRAGMENTS; TAU PROTEINS; YOUNG ADULT;

EID: 84934267939     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000207     Document Type: Article

References (130)

1. Montine T, Montine K, Swift L. Central nervous system lipoproteins in Alzheimer's disease. Am J Pathol 1997;151:1571-5
2. Koch S, Donarski N, Goetze K, et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 2001;42:1143-51
3. Borghini I, Barja F, Pometta D, et al. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta 1995;1255:192-200
4. Pitas RE, Boyles JK, Lee SH, et al. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 1987;262:14352-60
5. Roheim PS, Carey M, Forte T, et al. Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci U S A 1979;76:4646-9
6. Cruchaga C, Kauwe JS, Nowotny P, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum Mol Genet 2012;21:4558-71
7. Lehtimaki T, Pirttila T, Mehta PD, et al. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet 1995;95:39-42
8. Landen M, Hesse C, Fredman P, et al. Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. Dementia 1996;7:273-8
9. Mulder M, Ravid R, Swaab DF, et al. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis Assoc Disord 1998;12:198-203
10. Lefranc D, Vermersch P, Dallongeville J, et al. Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Neurosci Lett 1996;212:91-4
11. Schiele F, De Bacquer D, Vincent-Viry M, et al. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis 2000;152:475-88
12. Blennow K, Hesse C, Fredman P. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport 1994;5:2534-6
13. Beffert U, Cohn JS, Petit-Turcotte C, et al. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res 1999;843:87-94
14. Yamauchi K, Tozuka M, Nakabayashi T, et al. Apolipoprotein E in cerebrospinal fluid: relation to phenotype and plasma apolipoprotein E concentrations. Clin Chem 1999;45:497-504
15. Montine KS, Bassett CN, Ou JJ, et al. Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins. J Lipid Res 1998;39:2443-51
16. Merched A, Blain H, Visvikis S, et al. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J Neurol Sci 1997;145:33-9
17. Verghese PB, Castellano JM, Garai K, et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci U S A 2013;110:E1807-16
18. LaDu MJ, Munson GW, Jungbauer L, et al. Preferential interactions between ApoE-containing lipoproteins and Abeta revealed by a detection method that combines size exclusion chromatography with nonreducing gel-shift. Biochim Biophys Acta 2012;1821:295-302
19. Vollbach H, Heun R, Morris CM, et al. APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann Neurol 2005;58:436-41
20. Helbecque N, Codron V, Cottel D, et al. An apolipoprotein A-I gene promoter polymorphism associated with cognitive decline, but not with Alzheimer's disease. Dement Geriatr Cogn Disord 2008;25:97-102
21. Saczynski JS, White L, Peila RL, et al. The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am J Epidemiol 2007;165:985-92
22. Kawano M, Kawakami M, Otsuka M, et al. Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. Clin Chim Acta 1995;239:209-11
23. Merched A, Xia Y, Visvikis S, et al. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 2000;21:27-30
24. Liu HC, Hu CJ, Chang JG, et al. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement Geriatr Cogn Disord 2006;21:155-61
25. Wang ES, Sun Y, Guo JG, et al. Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. Acta Neurol Scand 2010;122:350-9
26. Qiang JK, Wong YC, Siderowf A, et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 2013;74:119-27
27. Maarouf CL, Beach TG, Adler CH, et al. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol Res 2012;34:669-76
28. Paula-Lima AC, Tricerri MA, Brito-Moreira J, et al. Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. Int J Biochem Cell Biol 2009;41:1361-70
29. Koldamova RP, Lefterov IM, Lefterova MI, et al. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 2001;40:3553-60
30. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:1094-9
31. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088-93
32. Ghiso J, Matsubara E, Koudinov A, et al. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 1993;293:27-30
33. Boggs LN, Fuson KS, Baez M, et al. Clusterin (Apo J) protects against in vitro amyloid-beta (1-40) neurotoxicity. J Neurochem 1996;67:1324-7
34. Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J-Alzheimer's A beta interaction. J Biol Chem 1995;270:7563-7
35. DeMattos RB, Cirrito JR, Parsadanian M, et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004;41:193-202
36. Desikan RS, Thompson WK, Holland D, et al. The role of clusterin in amyloid-beta-associated neurodegeneration. JAMA Neurol 2014;71:180-7
37. Prikrylova Vranova H, Mares J, Nevrly M, et al. CSF markers of neurodegeneration in Parkinson's disease. J Neural Transm 2010;117:1177-81
38. van Dijk KD, Jongbloed W, Heijst JA, et al. Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. Parkinsonism Relat Disord 2013;19:1079-83
39. Braccioli L, van Velthoven C, Heijnen CJ. Exosomes: a new weapon to treat the central nervous system. Mol Neurobiol 2014;49:113-9
40. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999;94:3791-9
41. Vader P, Breakefield XO, Wood MJ. Extracellular vesicles: emerging targets for cancer therapy. Trends Mol Med 2014;20:385-93
42. Gyorgy B, Szabo TG, Pasztoi M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011;68:2667-88
43. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009;9:581-93
44. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013;200:373-83
45. Burger D, Schock S, Thompson CS, et al. Microparticles: biomarkers and beyond. Clin Sci (Lond) 2013;124:423-41
46. Dachary-Prigent J, Freyssinet JM, Pasquet JM, et al. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 1993;81:2554-65
47. Vella LJ, Greenwood DL, Cappai R, et al. Enrichment of prion protein in exosomes derived from ovine cerebral spinal fluid. Vet Immunol Immunopathol 2008;124:385-93
48. Wang S, Cesca F, Loers G, et al. Synapsin I is an oligomannose-carrying glycoprotein, acts as an oligomannose-binding lectin, and promotes neurite outgrowth and neuronal survival when released via glia-derived exosomes. J Neurosci 2011;31:7275-90
49. Xin H, Li Y, Buller B, et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells 2012;30:1556-64
50. Morel L, Regan M, Higashimori H, et al. Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1. J Biol Chem 2013;288:7105-16
51. Zachau AC, Landen M, Mobarrez F, et al. Leukocyte-derived microparticles and scanning electron microscopic structures in two fractions of fresh cerebrospinal fluid in amyotrophic lateral sclerosis: a case report. J Med Case Rep 2012;6:274
52. Rajendran L, Honsho M, Zahn TR, et al. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A 2006;103:11172-7
53. Sharples RA, Vella LJ, Nisbet RM, et al. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J 2008;22:1469-78
54. Bulloj A, Leal MC, Xu H, et al. Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid-beta degrading protease. J Alzheimers Dis 2010;19:79-95
55. Saman S, Kim W, Raya M, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 2012;287:3842-9
56. Emmanouilidou E, Melachroinou K, Roumeliotis T, et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 2010;30:6838-51
57. Perez-Gonzalez R, Gauthier SA, Kumar A, et al. The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space. J Biol Chem 2012;287:43108-15
58. LaDu MJ, Gilligan SM, Lukens JR, et al. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem 1998;70:2070-81
59. Bassett CN, Neely MD, Sidell KR, et al. Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo. Lipids 1999;34:1273-80
60. Hesse C, Larsson H, Fredman P, et al. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res 2000;25:511-7
61. Wahrle SE, Shah AR, Fagan AM, et al. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener 2007;2:7
62. Chandler WL. Microparticle counts in platelet-rich and platelet-free plasma, effect of centrifugation and sample-processing protocols. Blood Coagul Fibrinolysis 2013;24:125-32
63. Lacroix R, Judicone C, Poncelet P, et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J Thromb Haemost 2012;10:437-46
64. Lacroix R, Robert S, Poncelet P, et al. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 2010;36:807-18
65. Orozco AF, Lewis DE. Flow cytometric analysis of circulating microparticles in plasma. Cytometry A 2010;77:502-14
66. Sokolow S, Henkins KM, Bilousova T, et al. Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease. J Neurochem 2014
67. Henkins KM, Sokolow S, Miller CA, et al. Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses. Brain Pathol 2012;22:826-33
68. Sokolow S, Henkins KM, Bilousova T, et al. AD synapses contain abundant Abeta monomer and multiple soluble oligomers, including a 56-kDa assembly. Neurobiol Aging 2012;33:1545-55
69. Postupna NO, Keene CD, Latimer C, et al. Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease. Lab Invest 2014;94:1161-72
70. Sokolow S, Luu SH, Nandy K, et al. Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex. Neurobiol Dis 2012;45:381-7
71. Chandler WL, Yeung W, Tait JF. A new microparticle size calibration standard for use in measuring smaller microparticles using a new flow cytometer. J Thromb Haemost 2011;9:1216-24
72. Robert S, Poncelet P, Lacroix R, et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? J Thromb Haemost 2009;7:190-7
73. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9
74. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9
75. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52
76. Li G, Millard SP, Peskind ER, et al. Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. JAMA Neurol 2014;71:742-51
77. Cholerton BA, Zabetian CP, Quinn JF, et al. Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis 2013;3:205-14
78. Peskind ER, Riekse R, Quinn JF, et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 2005;19:220-5
79. Nielsen MH, Beck-Nielsen H, Andersen MN, et al. A flow cytometric method for characterization of circulating cell-derived microparticles in plasma. J Extracell Vesicles 2014;3:doi: 10.3402/jev.v3.20795
80. Knouff C, Hinsdale ME, Mezdour H, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 1999;103:1579-86
81. Sullivan PM, Mezdour H, Aratani Y, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997;272:17972-80
82. Maezawa I, Maeda N, Montine TJ, et al. Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice. J Neuroinflammation 2006;3:10
83. Cudaback E, Li X, Montine KS, et al. Apolipoprotein E isoform-dependent microglia migration. FASEB J 2011;25:2082-91
84. Cudaback E, Li X, Yang Y, et al. Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation. J Neuroinflammation 2012;9:192
85. Li X, Rose SE, Montine KS, et al. Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid beta neurotoxicity in vitro. J Neuroimmune Pharmacol 2013;8:87-93
86. Carrillo MC, Blennow K, Soares H, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement 2013;9:137-40
87. Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007;69:631-9
88. Montine TJ, Shi M, Quinn JF, et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25:2682-5
89. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-80
90. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70:1277-87
91. Woltjer RL, Sonnen JA, Sokal I, et al. Quantitation and mapping of cerebral detergent-insoluble proteins in the elderly. Brain Pathol 2009;19:365-74
92. Suzuki T, Tozuka M, Kazuyoshi Y, et al. Predominant apolipoprotein J exists as lipid-poor mixtures in cerebrospinal fluid. Ann Clin Lab Sci 2002;32:369-76
93. Bertrand P, Poirier J, Oda T, et al. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res 1995;33:174-8
94. Page KJ, Hollister RD, Hyman BT. Dissociation of apolipoprotein and apolipoprotein receptor response to lesion in the rat brain: an in situ hybridization study. Neuroscience 1998;85:1161-71
95. Elshourbagy NA, Liao WS, Mahley RW, et al. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci U S A 1985;82:203-7
96. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res 2009;50(Suppl):S183-8
97. Eto M, Watanabe K, Ishii K. Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects. Clin Genet 1986;29:477-84
98. Gregg RE, Zech LA, Schaefer EJ, et al. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 1986;78:815-21
99. Hanis CL, Hewett-Emmett D, Douglas TC, et al. Effects of the apolipoprotein E polymorphism on levels of lipids, lipoproteins, and apolipoproteins among Mexican-Americans in Starr County, Texas. Arterioscler Thromb 1991;11:362-70
100. Riddell DR, Zhou H, Atchison K, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 2008;28:11445-53
101. Weisgraber KH. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res 1990;31:1503-11
102. Steinmetz A, Jakobs C, Motzny S, et al. Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis 1989;9:405-11
103. Reilly M, Rader DJ. Apolipoprotein E and coronary disease: a puzzling paradox. PLoS Med 2006;3:e258
104. Stampfer MJ. Cardiovascular disease and Alzheimer's disease: common links. J Intern Med 2006;260:211-23
105. Ramaswamy G, Xu Q, Huang Y, et al. Effect of domain interaction on apolipoprotein E levels in mouse brain. J Neurosci 2005;25:10658-63
106. Sullivan PM, Mace BE, Maeda N, et al. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 2004;124:725-33
107. Fryer JD, Simmons K, Parsadanian M, et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 2005;25:2803-10
108. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011;3:89ra57
109. Rebeck GW, Reiter JS, Strickland DK, et al. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-80
110. DeMattos RB, Brendza RP, Heuser JE, et al. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem Int 2001;39:415-25
111. Xu Q, Li Y, Cyras C, et al. Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle. J Biol Chem 2000; 275:31770-7
112. Yang Y, Cudaback E, Jorstad NL, et al. APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease. Am J Pathol 2013;183:905-17
113. Chen HK, Liu Z, Meyer-Franke A, et al. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J Biol Chem 2012;287:5253-66
114. Han SH, Einstein G, Weisgraber KH, et al. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J Neuropathol Exp Neurol 1994;53:535-44
115. Metzger RE, LaDu MJ, Pan JB, et al. Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:372-80
116. Xu PT, Gilbert JR, Qiu HL, et al. Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol 1999;154:601-11
117. Brecht WJ, Harris FM, Chang S, et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 2004;24:2527-34
118. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:8098-102
119. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 1996;19:53-77
120. LaDu MJ, Falduto MT, Manelli AM, et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 1994;269:23403-6
121. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997;17:263-4
122. Permanne B, Perez C, Soto C, et al. Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 1997;240:715-20
123. Holtzman DM, Bales KR, Wu S, et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest 1999;103:R15-r21
124. Yu C, Youmans KL, LaDu MJ. Proposed mechanism for lipoprotein remodelling in the brain. Biochim Biophys Acta 2010;1801:819-23
125. Lefterov I, Fitz NF, Cronican AA, et al. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J Biol Chem 2010;285:36945-57
126. Lewis TL, Cao D, Lu H, et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem 2010;285:36958-68
127. Chambenoit O, Hamon Y, Marguet D, et al. Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter. J Biol Chem 2001;276:9955-60
128. Smith JD, Waelde C, Horwitz A, et al. Evaluation of the role of phosphatidylserine translocase activity in ABCA1-mediated lipid efflux. J Biol Chem 2002;277:17797-803
129. Lindh M, Blomberg M, Jensen M, et al. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett 1997;229:85-8
130. Fagan AM, Holtzman DM, Munson G, et al. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J Biol Chem 1999;274:30001-7